



TABLE OF CONTENTS

1. INTRODUCTION	1
2. LITERATURE REVIEW	11
2.1 Central Nervous System	12
2.2 Barriers to CNS Drug Delivery	12
2.3 Strategies for enhanced CNS drug delivery	15
2.4 Intranasal delivery for brain targeting	18
2.4.1 The nose.....	19
2.4.2 Nasal Drug Delivery – Advantages/Disadvantages.....	20
2.4.3 Mechanisms of nasal drug absorption	22
2.4.4 Intranasal pathways of drug transport to the brain	23
2.4.5 Factors affecting transnasal drug absorption	26
2.4.5 Intranasal formulations for transnasal drug delivery	37
2.5 Nanoparticles for transnasal drug delivery.....	42
2.5.1 Techniques for preparation of nanoparticles.....	43
2.5.2 Techniques for characterization of nanoparticles.....	47
2.5.3 Nanoparticles conjugated to ligands for receptor mediated transcytosis.....	47
2.6 Microemulsions for transnasal drug delivery	48
2.6.1 Factors influencing type of microemulsion formed.....	50
2.6.2 Formation of microemulsion and phase behavior	52
2.6.3 Formulation of microemulsions.....	54
2.6.4 Methods for construction of phase diagram	54
2.6.4 Characterization of microemulsions	55
2.7 Mucoadhesive Agents.....	58
2.7.1 Mechanism and theory of bioadhesion	58
2.8 Cerebral ischemia or stroke	59
2.9.1 Pathophysiology of ischemic stroke	60
2.9.2 Pharmacological approaches to the problem of cerebral ischemia or stroke.....	62
2.9 Obesity	61
2.9.1 Pathophysiology of obesity.....	63

2.9.2 Pharmacological approaches to the problem of obesity	65
2.10 Drug Profile	66
2.10.1 Nicergoline	66
2.10.2 Hydergine or ergoloid mesylate.....	67
2.10.3 Sibutramine hydrochloride monohydrate	68
References.....	69
3. ANALYTICAL METHODS	82
3.1 Nicergoline	84
3.1.1 Estimation of nicergoline in solution and nanoparticles.....	85
3.1.1.1 Estimation of nicergoline in solution.....	85
3.1.1.2 Estimation of nicergoline in nanoparticles	87
3.1.1.3 Estimation of nicergoline for <i>in-vitro</i> release.....	87
3.1.2 Estimation of nicergoline in solution and microemulsion.....	88
3.1.2.1 Estimation of nicergoline in solution.....	88
3.1.2.2 Estimation of nicergoline in ME and MME	90
3.1.2.3 Estimation of nicergoline for <i>in-vitro</i> release.....	90
3.2 Sibutramine	91
3.2.1 Estimation of sibutramine base in solution and NPs	91
3.2.1.1 Estimation of sibutramine base in solution.....	91
3.2.1.2 Estimation of sibutramine base in NPs.....	93
3.2.1.3 Estimation of sibutramine base for <i>in-vitro</i> release.....	93
3.2.2 Estimation of sibutramine base in solution and microemulsion.....	94
3.2.2.1 Estimation of sibutramine base in solution.....	94
3.2.2.2 Estimation of sibutramine base in ME and MME	96
3.2.2.3 Estimation of sibutramine base for <i>in-vitro</i> release.....	96
3.3 Hydergine	96
3.3.1 Estimation of hydergine in solution and NPs	97
3.3.1.1 Estimation of hydergine in solution.....	97
3.3.1.2 Estimation of hydergine in NPs.....	99
3.3.1.3 Estimation of hydergine for <i>in-vitro</i> release.....	99
3.3.2 Estimation of hydergine in solution and microemulsion.....	99

3.3.2.1 Estimation of hydergine in solution.....	99
3.3.2.2 Estimation of hydergine in ME and MME	101
3.3.2.3 Estimation of hydergine for <i>in-vitro</i> release	102
3.4 Determination of phycoerythrin-conjugated-anti-mouse-anti-transferrin-receptor monoclonal antibody (PE-mAb-Tfr) by spectrofluorometry.....	102
3.4.1 Estimation of PE-mAb-Tfr in solution	102
3.5 Discussion.....	105
References.....	106
4. PREPARATION, OPTIMIZATION, ANTIBODY CONJUGATION AND CHARACTERI- ZATION OF NANOPARTICLES	109
4.1 Methods	114
4.1.1 Precipitation of sibutramine base (SB) from Sibutramine hydrochloride monohydrate (SBHM) salt.....	114
4.1.2 Preparation and optimization of nanoparticles	114
4.1.3 Lyophilization and optimization of cryoprotectant concentration.....	120
4.1.4 Antibody conjugation of nanoparticles.....	120
4.1.5 Characterization of nanoparticles	123
4.2 Results.....	126
4.2.1 Precipitation of sibutramine base (SB) from Sibutramine hydrochloride monohydrate (SBHM) salt.....	126
4.2.2 Preparation and optimization of nanoparticles	126
4.2.3 Lyophilization and optimization of cryoprotectant concentration.....	137
4.2.4 Antibody conjugation of nanoparticles.....	138
4.2.5 Characterization of nanoparticles	139
4.3 Discussion.....	148
4.3.1 Precipitation of sibutramine base (SB) from Sibutramine hydrochloride monohydrate (SBHM) salt.....	148
4.3.2 Preparation and optimization of nanoparticles	148
4.3.3 Lyophilization and optimization of cryoprotectant concentration.....	154
4.3.4 Antibody conjugation of nanoparticles.....	156
4.3.5 Characterization of nanoparticles	158

4.4 Conclusion	162
References.....	162
5. PREPARATION, OPTIMIZATION AND CHARACTERIZATION OF MICROEMULSIONS.....	166
5.1 Methods	168
5.1.1. Preparation of microemulsions and mucoadhesive microemulsions.....	168
5.1.2. Characterization of microemulsions and mucoadhesive microemulsions.....	173
5.1.3. Stability study	177
5.1.4. Statistical analysis.....	177
5.2 Results.....	178
5.2.1. Preparation of microemulsions and mucoadhesive microemulsions.....	178
5.2.2. Characterization of microemulsions and mucoadhesive microemulsions.....	185
5.2.3. Stability study	192
5.3 Discussion.....	193
5.3.1. Preparation of microemulsions and mucoadhesive microemulsions.....	193
5.3.2. Characterization of microemulsions and mucoadhesive microemulsions.....	198
5.4 Conclusion	200
References.....	200
6 PHARMACOKINETIC STUDIES	203
6.1 Radiolabelling of formulations	207
6.1.1 Materials	207
6.1.2 Methods	207
6.2 Pharmacokinetic studies	209
6.2.1 Methods	209
6.2.1.1 Animals.....	209
6.2.1.2 Pharmacokinetics of radiolabelled formulations	209
6.2.1.3 Statistical analysis.....	211
6.2.1.4 Gamma scintigraphy studies.....	211
6.3 Results.....	212
6.4 Discussion.....	224
6.5 Conclusion	225

References.....	226
7. PHARMACODYNAMIC STUDIES	228
7.1 Evaluation of anti-obesity effect of sibutramine	229
7.1.1 Animals.....	229
7.1.2 Methods	229
7.1.3 Statistical analysis.....	233
7.2 Evaluation of anti-ischemic effect of nicergoline.....	233
7.2.1 Animals.....	233
7.2.2 Methods	234
7.2.3 Statistical analysis.....	238
7.3 Results.....	238
7.4 Discussion.....	240
7.5 Conclusion	241
References.....	242
8. SUMMARY AND CONCLUSIONS.....	245